Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BIOA
BioAge Labs
$4.37
+4.5%
$0.00
$2.88
$26.62
$156.66MN/A280,685 shs125,696 shs
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
$6.66
+0.5%
$6.68
$6.08
$16.76
$675.06M-1.271.25 million shs300,217 shs
Evolus, Inc. stock logo
EOLS
Evolus
$9.23
+1.0%
$9.93
$8.67
$17.82
$595.15M0.97939,286 shs254,769 shs
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
$5.92
-0.5%
$6.27
$2.36
$7.48
$694.36M0.461.42 million shs697,936 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BIOA
BioAge Labs
-2.34%+1.21%+417,999,900.00%+417,999,900.00%+417,999,900.00%
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-2.50%+2.00%-7.79%-1.19%-51.64%
Evolus, Inc. stock logo
EOLS
Evolus
-1.40%-0.76%-8.96%-2.35%-16.38%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
+0.92%+8.78%-15.72%+12.26%+130.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BIOA
BioAge Labs
N/AN/AN/AN/AN/AN/AN/AN/A
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
1.7243 of 5 stars
3.62.00.00.00.02.50.0
Evolus, Inc. stock logo
EOLS
Evolus
3.6796 of 5 stars
3.50.00.03.51.13.30.6
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
3.1265 of 5 stars
4.71.00.00.02.52.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BIOA
BioAge Labs
0.00
N/AN/AN/A
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
3.14
Buy$29.00335.44% Upside
Evolus, Inc. stock logo
EOLS
Evolus
3.00
Buy$23.75157.31% Upside
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
3.30
Buy$20.88252.62% Upside

Current Analyst Ratings Breakdown

Latest BIOA, DAWN, TRVI, and EOLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$25.00
6/2/2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
6/2/2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$21.00
5/28/2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$21.00
5/20/2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
5/8/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
5/7/2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$25.00
5/7/2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $27.00
4/17/2025
Evolus, Inc. stock logo
EOLS
Evolus
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
4/10/2025
Evolus, Inc. stock logo
EOLS
Evolus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
4/9/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BIOA
BioAge Labs
N/AN/AN/AN/A$9.01 per shareN/A
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
$131.16M5.15N/AN/A$4.99 per share1.33
Evolus, Inc. stock logo
EOLS
Evolus
$266.27M2.24N/AN/A$0.09 per share102.56
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/AN/AN/AN/A$1.30 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BIOA
BioAge Labs
-$71.11MN/A0.00N/AN/AN/AN/AN/A
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-$95.50M-$0.71N/AN/AN/A-42.66%-14.98%-13.04%7/8/2025 (Estimated)
Evolus, Inc. stock logo
EOLS
Evolus
-$50.42M-$0.89N/AN/AN/A-20.40%-759.04%-20.14%7/30/2025 (Estimated)
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
-$47.91M-$0.45N/AN/AN/AN/A-58.41%-52.52%8/6/2025 (Estimated)

Latest BIOA, DAWN, TRVI, and EOLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Evolus, Inc. stock logo
EOLS
Evolus
-$0.09N/AN/AN/A$82.18 millionN/A
7/29/2025Q2 2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-$0.35N/AN/AN/A$35.55 millionN/A
5/6/2025Q1 2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million
5/6/2025Q1 2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
-$0.13-$0.09+$0.04-$0.09N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BIOA
BioAge Labs
N/AN/AN/AN/AN/A
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
N/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BIOA
BioAge Labs
N/A
13.68
13.68
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
N/A
10.62
10.55
Evolus, Inc. stock logo
EOLS
Evolus
22.00
2.34
2.16
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/A
15.38
15.38

Institutional Ownership

CompanyInstitutional Ownership
BIOA
BioAge Labs
N/A
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
87.95%
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
95.76%

Insider Ownership

CompanyInsider Ownership
BIOA
BioAge Labs
20.82%
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
6.20%
Evolus, Inc. stock logo
EOLS
Evolus
6.10%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
18.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
BIOA
BioAge Labs
N/A35.85 million28.39 millionN/A
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
60101.36 million95.08 millionOptionable
Evolus, Inc. stock logo
EOLS
Evolus
17064.48 million60.54 millionOptionable
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
20117.29 million95.83 millionOptionable

Recent News About These Companies

Cantor Fitzgerald Predicts TRVI FY2025 Earnings
TRVI Trevi Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioAge Labs NASDAQ:BIOA

$4.37 +0.19 (+4.55%)
As of 01:56 PM Eastern

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

Day One Biopharmaceuticals stock logo

Day One Biopharmaceuticals NASDAQ:DAWN

$6.66 +0.03 (+0.45%)
As of 01:57 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Evolus stock logo

Evolus NASDAQ:EOLS

$9.23 +0.09 (+0.98%)
As of 01:58 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Trevi Therapeutics stock logo

Trevi Therapeutics NASDAQ:TRVI

$5.92 -0.03 (-0.50%)
As of 01:57 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.